impact factor
logo
 

shopping cart

Confirmation
purchase
Item
Code
Item DescriptionPrice
CER14356Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study20.00 €
 Subtotal 20.00 €